Boc-DOPA-(Bn)2-OH | 19937-29-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-DOPA-(Bn)2-OH
• 英文别名: N-(tert-Butoxycarbonyl)-3,4-dibenzyloxyphenylalanine；rac.3,4-Dibenzyloxy-N-tert.-butoxy-phenyl-alanin；DL-Boc-Dopa-(Bzl)2；3-[3,4-Bis(phenylmethoxy)phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 19937-29-2
• 化学式: C₂₈H₃₁NO₆
• 分子量: 477.557
• InChiKey: LJQMOXCGNBXRJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  94.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Boc-DOPA-(Bn)2-OH 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 H2N-DOPA-(Bn)2-OH*HCl
  参考文献：
  名称：

  Self-Assembly of Focal Point Oligo-catechol Ethylene Glycol Dendrons on Titanium Oxide Surfaces: Adsorption Kinetics, Surface Characterization, and Nonfouling Properties

  摘要：

  This work covers the synthesis of second-generation, ethylene glycol dendrons covalently linked to a surface anchor that contains two, three, or four catechol groups, the molecular assembly in aqueous buffer on titanium oxide surfaces, and the evaluation of the resistance of the monomolecular adlayers against nonspecific protein adsorption in contact with full blood serum. The results were compared to those of a linear poly(ethylene glycol) (PEG) analogue with the same molecular weight. The adsorption kinetics as well as resulting surface coverages were monitored by ex situ spectroscopic ellipsometry (VASE), in situ optical waveguide lightmode spectroscopy (OWLS), and quartz crystal microbalance with dissipation (QCM-D) investigations. The expected compositions of the macromolecular films were verified by X-ray photoelectron spectroscopy (XPS). The results of the adsorption study, performed in a high ionic strength ("cloud-point") buffer at room temperature, demonstrate that the adsorption kinetics increase with increasing number of catechol binding moieties and exceed the values found for the linear PEG analogue. This is attributed to the comparatively smaller and more confined molecular volume of the dendritic macromolecules in solution, the improved presentation of the catechol anchor, and/or their much lower cloud-point in the chosen buffer (close to room temperature). Interestingly, in terms of mechanistic aspects of "nonfouling" surface properties, the dendron films were found to be much stiffer and considerably less hydrated in comparison to the linear PEG brush surface, closer in their physicochemical properties to oligo(ethylene glycol) alkanethiol self-assembled monolayers than to conventional brush surfaces. Despite these differences, both types of polymer architectures at saturation coverage proved to be highly resistant toward protein adsorption. Although associated with higher synthesis costs, dendritic macromolecules are considered to be an attractive alternative to linear polymers for surface (bio)functionalization in view of their spontaneous formation of ultrathin, confluent, and nonfouling monolayers at room temperature and their outstanding ability to present functional ligands (coupled to the termini of the dendritic structure) at high surface densities.

  DOI：

  10.1021/ja202760x
• 作为产物：
  描述：

  氯化苄 在 sodium hydroxide 、 potassium carbonate 、 sodium iodide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 4.0h， 生成 Boc-DOPA-(Bn)2-OH
  参考文献：
  名称：

  人体血浆中取代的儿茶酚咪唑啉和儿茶酚咪唑类似物的合成及其α2-肾上腺素受体的作用。

  摘要：

  已知儿茶酚胺和儿茶酚酰咪唑啉与α1和α2肾上腺素受体相互作用的空间要求是不同的。Deoxycatecholimidazoline（1），desoxycatecholimidazole（3），苄基羟基取代的咪唑（4）的新类似物以及在2（5），5（6）和6（7）位置处的芳族氟取代类似物1和制备一组不对称的4-取代的儿茶酚咪唑啉S-8和R-8，并测试与人血小板中的α2-肾上腺素受体的相互作用。除3外，所有化合物均对人血小板中α-肾上腺素受体介导的反应具有选择性。在咪唑啉1中引入双键以生成咪唑3或在3中引入苄基羟基，如在图4中所示：降低了对血小板凝集的抑制，等级效力为1大于3大于4。2位，5位或6位的氟原子取代仅轻微改变了1的抑制活性。每个类似物（1、3 -7）产生α2介导的对血小板腺苷酸环化酶的抑制作用，可以归类为部分激动剂。S-8和R-8对肾上腺素诱导的聚集反应的抑制力有很大不同，只有R-8和

  DOI：

  10.1021/jm00166a009

文献信息

• AMINO ACID DERIVATIVES
  申请人：Hobbs Christopher

  公开号：US20090239941A1

  公开（公告）日：2009-09-24

  Compounds of formula (I) are active as dopaminergic compounds or as compounds which or as compounds which diminish the symptoms of dopamine deficiency: wherein: R 1 and R 2 are independently selected from —C(═O)R 5 or —C(═O)OR 5 ; or one of R 1 and R 2 is hydrogen and the other is —C(═O)R 5 or —C(═O)OR 5 ; R 3 and R 4 are independently selected from hydrogen, optionally substituted C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, —CH2Q, —C(═O)R 5 , —C(═O)OR 5 , —C(═O)NR 5 R 6 , or R 5 is hydrogen or optionally substituted C 1 -C 6 alkyl or —CH 2 Q; R 6 is hydrogen or optionally substituted C 1 -C 6 alkyl Or —CH 2 Q; and Q is an optionally substituted monocyclic carbocyclic or heterocyclyl ring of 3 to 6 ring atoms.

  式(I)的化合物具有作为多巴胺能化合物的活性，或作为减轻多巴胺缺乏症状的化合物，其中：R1和R2独立地选自—C（═O）R5或—C（═O）OR5；或者R1和R2中的一个是氢，另一个是—C（═O）R5或—C（═O）OR5；R3和R4独立地选自氢，可选取代的C1-C6烷基，C3-C6环烷基，C2-C6烯基或C2-C6炔基，—CH2Q，—C（═O）R5，—C（═O）OR5，—C（═O）NR5R6，其中R5是氢或可选取代的C1-C6烷基或—CH2Q；R6是氢或可选取代的C1-C6烷基或—CH2Q；Q是具有3至6个环原子的可选取代的单环碳环或杂环基。
• TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
  申请人：Onyx Therapeutics, Inc.

  公开号：US20140336106A1

  公开（公告）日：2014-11-13

  Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.

  本文提供了三肽环氧酮蛋白酶抑制剂及其制备方法、相关药物组合物和使用方法。例如，本文提供了式（X）的化合物及其药物可接受的盐和组合物。本文提供的化合物和组合物可以用于治疗包括炎症和神经退行性疾病在内的疾病。
• Tripeptide epoxy ketone protease inhibitors
  申请人：Onyx Therapeutics, Inc.

  公开号：US10647744B2

  公开（公告）日：2020-05-12

  Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.

  本文提供了三肽环氧酮蛋白酶抑制剂、其制备方法、相关药物组合物以及使用方法。例如，本文提供了式 (X) 的化合物： 和药学上可接受的盐以及包括它们的组合物。本文提供的化合物和组合物可用于治疗包括炎症和神经退行性疾病在内的各种疾病。
• EP1993995A1
  申请人：——

  公开号：EP1993995A1

  公开（公告）日：2008-11-26
• Method of preparing dendritic drugs
  申请人：Chai Minghui

  公开号：US20070190151A1

  公开（公告）日：2007-08-16

  Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.